ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177June 23, 2020 - Garching/Munch, Germany & Toronto - ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical...
POINT Biopharma to Launch First US Manufacturing Facility in IndianaMay 26, 2020 – INDIANAPOLIS - POINT Biopharma (POINT) announced plans today to establish its first U.S. manufacturing facility in India...
POINT Biopharma Announces Phase 3 Prostate Cancer TrialMay 12, 2020 - Toronto - POINT Biopharma Inc. is pleased to announce the selection of PSI CRO to manage its phase 3 clinical study of PNT...
POINT Biopharma Announces Global Prostate Oncology Therapeutic Board of AdvisorsApril 7, 2020 - Toronto - POINT Biopharma Inc. is pleased to announce the formation of its global prostate oncology therapeutic advisory ...
POINT Biopharma Announces Manufacturing Leadership and Search for US manufacturing siteMarch 24, 2020 - Toronto - POINT Biopharma Inc. today announced the appointment of Todd Hockemeyer as Executive Vice President of US M...
POINT Biopharma and SCINTOMICS Announce License AgreementMarch 10, 2020 - TORONTO and MUNICH, Germany - POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMI...
Point Biopharma launches with Radiopharmaceutical development focusFeb. 25, 2020 - Toronto - POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strateg...
